Skip to main content

GRI Bio, Inc.

corporate_fare Company Profile

GRI Bio, Inc.

GRI·NASDAQ·Life Sciences·CIK 0001824293

We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for serious diseases linked to dysregulated immune responses, specifically inflammatory, fibrotic, and autoimmune disorders. Our primary product candidate is GRI-0621, an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells. The active pharmaceutical ingredient in GRI-0621 is tazarotene, a synthetic retinoid acid receptor-beta and gamma selective agonist. Tazarotene is currently approved in the United States for topical treatment of psoriasis and acne. Although there are no approved oral formulations of tazarotene, as of December 31, 2025, it has been evaluated in over 1,700 patients as an oral product for up to 52 weeks. We are developing GRI-0621 to treat severe fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF). IPF is a progressive fibrotic lung disease affecting approximately 140,000 people in the United States, with up to 40,000 new cases annually in the United States, and an estimated 3 million globally. While two approved therapies exist for lung fibrosis, they have not improved overall survival and are associated with significant side effects leading to poor patient adherence. Preliminary and topline data from our trials with GRI-0621, and earlier trials with oral tazarotene, indicate that GRI-0621 is well-tolerated and inhibits iNKT cell activity. Activated iNKT cells are elevated in patients with IPF, primary sclerosing cholangitis (PSC), metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD), systemic lupus erythematosus (SLE), multiple sclerosis (MS), and ulcerative colitis (UC), and correlate with more severe disease. We recently evaluated GRI-0621 in a randomized, double-blind, multi-center, 2-arm Phase 2a clinical trial for IPF patients.

GRI Bio, Inc. (NASDAQ:GRI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for GRI at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • GRI Bio Expands At-The-Market Offering to $7.38M, Indicating Substantial Dilution
  • GRI Bio Reports Positive Phase 2a Data for IPF Drug, Confirms Nasdaq Equity Compliance

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$11.96M
Diluted EPS
-$121.80
Op. Cash Flow
-$10.19M
Free Cash Flow
-$10.19M
Operating Income
-$11.98M
Cash & Equivalents
$8.23M
Debt / Equity
0.00×
Shares Outstanding
497.69K sh
Source: 10-K · filed 2026-01-30 · accession 0001824293-26-000033
$1.12
52-week range · as of 2026-11-13 $1.12 – $64.12
Market cap
$2.45M
Volume
25.1K (0.5× avg)
3-mo avg 46.2K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GRI - Filings & News (Page 2)

GRI
Jan 09, 2026, 8:31 AM EST
Filing Type: 424B5
Importance Score:
9
Price at Filing: $0.2823
Real-time Price: $1.12 info
Change: Reverse Stock Split info
Market Cap: $2.448M info
GRI
Jan 08, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.346
Real-time Price: $1.12 info
Change: Reverse Stock Split info
Market Cap: $2.448M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets